Lymphoma Hub
@lymphomahub
Followers
10,016
Following
2,299
Media
4,992
Statuses
10,640
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia. #lymsm
Global
Joined July 2013
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Jack Smith
• 460598 Tweets
FEMA
• 449115 Tweets
Messi
• 168089 Tweets
SURPRISE FROM BECKY
• 142344 Tweets
Kalafina
• 97635 Tweets
Maui
• 93991 Tweets
Padres
• 76644 Tweets
Royals
• 61938 Tweets
Junior
• 59435 Tweets
Orioles
• 44570 Tweets
Inter Miami
• 43494 Tweets
GOLD RUSH
• 35460 Tweets
Brewers
• 32329 Tweets
Braves
• 31461 Tweets
プロデューサー
• 27037 Tweets
学園アイドルマスター
• 26383 Tweets
#नवरात्रि
• 23309 Tweets
岡田監督
• 22032 Tweets
Sant Shri Asharamji Bapu
• 21163 Tweets
梶浦さん
• 19008 Tweets
Shakti Upasana
• 18570 Tweets
#今年も新作スイーツラテ飲みたーーーーい
• 18301 Tweets
Saint Dr MSG Insan
• 17991 Tweets
ميسي
• 17636 Tweets
Mendoza
• 16574 Tweets
渋沢栄一
• 15192 Tweets
マナー講師
• 15164 Tweets
#もうすぐ三角チョコパイの季節
• 14982 Tweets
マナー違反
• 13630 Tweets
藤川球児
• 12997 Tweets
Dalmau
• 12301 Tweets
Pinned Tweet
📅 Save the date!
On Wednesday, October 23, join our free virtual symposium chaired by
@gilles_salles
.
Registration is now open:
#lymsm
1
6
7
Check out the agenda for the upcoming virtual
#LymHubSS
! We’re excited to bring you four fantastic presentations and a round table discussion on ‘How I treat R/R disease - DLBCL and CLL! For more information visit:
#ESHLYMPHOMA2020
#lymsm
1
13
838
Not long now until the
@lymphomahub
Satellite Symposium
#LymHubSS
at 15-ICML 2019! Find out more here 👉. See you there!
#Lymsm
1
21
295
During
#ASH23
, updates from three key trials evaluating ctDNA as a tool to predict treatment response in patients with DLBCL were presented.
Read more here 👉
#lymsm
#lymphoma
#MedEducation
1
10
168
⏪Throwback to
@ASCO
2018 when we spoke to Loretta Nastoupil from
@MDAndersonNews
on the checkpoint inhibitors in
#lymphoma
. Stay tuned
@LymphomaHub
for the latest updates from
#ASCO19
🌎
#lymsm
0
9
133
Professor
@HallekMichael
of
@UniCologne
will be discussing
#CLL
at the
#LymHubSS
at 15-ICML 2019! Ask him a question on the novel
#ChemoFree
treatment approaches for CLL here 👉
#Lymsm
0
6
84
📢 Are you interested in joining our interactive discussion on therapies in B-cell malignancies, co-hosted by the
#Lymphoma
Hub and
@MM_Hub
at
@EHA_Hematology
? Attend virtually or in person and receive 1.5 CME credits of EBAH accreditation!
#EHA2024
#lymsm
#mmsm
#multiplemyeloma
4
5
85
On June 15, you can join our symposium at
@EHA_Hematology
for 1.5 CME credits of EBAH accreditation!
#EHA2024
#lymsm
#mmsm
@ESHaematology
@EliLymphoma
@MM_Hub
1
10
67
CONGRESS |
#SOHO2024
@gilles_salles
@MSKCancerCenter
discusses how to sequence therapies in R/R DLBCL, with the aim to optimize the chance of cure; concluding with a look to the future landscape and the possibility of achieving a cure amongst a substantial fraction of patients.
0
26
65
💉 Does a third SARS-CoV-2 booster vaccine improve humoral and T-cell-mediated immune responses in patients with lymphoid malignancies who failed to respond to their previous two doses?
1
16
55
🎥 VIDEO |
@gilles_salles
of
@CHUdeLyon
shares his excitement for the
#LymHubSS
at 15-ICML 2019! He will discuss novel
#ChemoFree
treatment approaches for lymphoid malignancies w/
@DrNathanFowler
@HallekMichael
@rule_simon
@DrAnasYounes
& Ulrich Jäger 👉
1
6
48
CONGRESS
#EHA2024
| Peter Borchmann
#cioabcd
presents the final analysis of phase III
#HD21
trial of PET2-individualized BrECADD regimen vs intensified BEACOPP in patients with advanced-stage
#HodgkinLymphoma
. BrECADD had superior efficacy (PFS 94.3% vs 90.9% at 4 yr) with
0
26
56
Which of the following patient populations do you feel represents a significant unmet need in Waldenstrom's macroglobulinemia?
BTKi failure/intolerant
9
MYD88 WT/CXCR4 mutation
12
Baseline neuropathy
17
CNS disease
7
2
5
53
If a potential new radiotherapy regimen achieved the following results for Waldenstrom's macroglobulinemia patients at a median of four lines of therapy, which data point would be the most persuasive in influencing your treatment decisions?
75% overall response rate
25
60% major response rate
18
100% disease control rate
30
4
2
48
🚨 N E W S 🚨
Zandelisib receives orphan drug designation by the
@US_FDA
for the treatment of follicular
#lymphoma
. Read the update on this oral PI3Kδ inhibitor on the
#LymphomaHub
👉 👈
#lymsm
#FL
0
6
46
⏪
#Throwback
to EHA 2018! The
@lymphomahub
spoke with
@AstridPavlovsky
on the hodgkin lymphoma highlights. Have a look at our coverage from last year’s EHA meeting before you head to
#Amsterdam
#EHA24
0
5
42
The countdown is on for the Lymphoma Hub Satellite Symposium NEXT WEEK!
#LymHubSS
Visit for all the details including how you can register to attend!
#ESHLYMPHOMA20
#lymsm
0
11
46
Have you caught up with our expert speakers discussing the ins and outs of CAR T cells in the real world?
Check out how CAR T-cell therapies are implemented in
#lymphoma
and
#multiplemyeloma
.
👉
#CART
#CARTcells
#lymsm
#mmsm
10
4
42
CONGRESS
#EBMT24
| Catherine Thieblemont
@HopSaintLouis
discussed about which patient should get an auto-HSCT in the CAR T-cell therapy era covering various aspects of patients with DLBCL, PCNSL, MCL & FL.
@TheEBMT
#lymphoma
#lymsm
#medicalcongress
2
10
41
CONGRESS |
#ASCO21
| Jia Ruan,
@WeillCornell
, highlights the potential of romidepsin + lenalidomide for the treatment of PTCL. In a phase II study, the chemo-free combination demonstrated an ORR of 75% (30% CR), which increased to 85% (39% CR) in patients with AITL.
#lymsm
@ASCO
0
16
39
CONGRESS
#EHA2024
| Arnon P. Kater
@amsterdamumc
shared early results of the EPCORE CLL-1 trial of epcortitamab in Richter's transformation (RT). N=35, mFU=8.1 mo, ORR was 53% (60% & 44% in 1L RT & 2L RT, resp), CR rate was 42% (50% & 33% in 1L RT & 2L RT, resp), OS was 11.7 mo,
0
10
37
CONGRESS
#ASCO22
| Stephen Ansell
@MayoClinic
reports on 6 year follow-up of the ECHELON-1 trial of pts with stage III/ IV cHL of A+AVD vs ABVD. OS favored A+AVD vs ABVD (p = 0.009). Estimated 6-year OS rates were 93.9% vs 89.4% with A+AVD vs ABVD, respectively.
#lymphoma
#lymsm
1
12
38
CONGRESS
#EHA2024
| Late-breaking |
@michaelwangmd
@MDAndersonNews
reports phase 3 ECHO trial of acalabrutinib (A) plus bendamustine (B) and rituximab (R) vs placebo (P) BR in untreated MCL. N=598, mFU=17 mo, mPFS=66.4 mo & 49.6 mo with ABR & PBR, resp; P=0.0160. OS was positive
3
16
38
CONGRESS |
#ASCO20
| MURANO phase III trial |
@anthonymatomd
, of
@MSKCC_OncoNotes
, reports a new analysis about the impact on survival outcomes of venetoclax early discontinuation, interruption, or dose modification when combined with rituximab to treat patients with R/R
#CLL
0
13
37
CONGRESS |
#IACH2021
| Waldenström’s macroglobulinemia field is advancing quickly!
@thanosdimop
gives a practical talk on its current management and some upcoming novel targeted therapies
#lymsm
@TheIACH
1
10
37
CONGRESS |
#ASCO21
|Caron Jacobson,
@DanaFarber
, presents the data from a subanalysis of the ZUMA-5 trial evaluating patients with iNHL who had progression of disease within 24 months of starting CIT (POD24). Axi-cel demonstrated durable responses in this high-risk population.
1
8
34
CONGRESS | Getting to the end of
#IACH2021
with
@AnnaSureda5
and her summary of CAR T cell therapies for DLBCL and FL. Of note, initial RWD is in line with CT in terms of efficacy and toxicity, but how to better determine patient eligibility to CAR-Ts?
@TheIACH
#lymsm
#lymphoma
1
11
35
CONGRESS |
#EHA2024
In the plenary abstracts session, Jeremy Abramson
@harvardmed
presents the phase III STARGLO trial of the CD20xCD3 bispecific antibody glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) vs rituximab plus GemOx (R-GemOx) in R/R DLBCL.
▪️ Primary
0
16
34
CONGRESS
#EBMT24
|
@gloria_iacoboni
@Hemato_Vhebron
discussed immunotherapeutic approaches in the treatment of
#lymphoma
highlighting key data from CAR T-cell therapy, bispecific antibodies, the novel immunotherapies, and the sequencing strategies.
@TheEBMT
#lymsm
1
11
33
#LLMCongress2021
|
@drsarahruth
@weillcornell
talks about the 4 novel agents approved for recurrent DLBCL: polatuzumab vedotin (w/bendamustine +rituximab), tafasitamab (w/lenalidomide), selinexor, and loncastuximab tesirine
#lymsm
1
13
31
CONGRESS |
#ASH23
| Franck Morschhauser, University of Lille, presents a post-hoc analysis of the POLARIX study on the prevalence & clinical outcomes of molecularly defined subtypes of DLBCL. N=594, high-risk DHL/THL patients with DZsigPos DLBCL may benefit from Pola-R-CHP vs
1
13
31
A new study published in
@TheLancetHaem
found that epcoritamab was associated with an ORR of 82% in patients with R/R follicular
#lymphoma
📝
More news:
#lymsm
#MedNews
#MedEd
0
8
32
#ESMO22
│ Clemens-Martin Wendtner from
@muenchenklinik
presents his expert opinion on the first line treatment of
#CLL
, including latest clinical trial data, toxicities with
#BTKi
, when to use obinutuzumab as choice of anti-CD20 and novel
#CLL
guidelines
#leusm
#medicalcongress
1
8
32
CONGRESS |
#SOHO2021
Loretta Nastoupil
@LeukemiaMDA
@MDAndersonNews
@CancerMedMDA
gives a great overview of
#CARTcell
therapy in
#lymphoma
during the independent satellite session, highlighting that CAR T cell therapy has transformed the management of DLBCL
#lymsm
0
7
32
Turning up to the
@lymphomahub
Executive Steering Committee in style!
#ASH18
#lymsm
@DrAnasYounes
@DrNathanFowler
@MarekTrnenyDr
1
4
30
#EHA2022
|
@AnnaSureda5
presented a subgroup analysis of ZUMA-7. Second line axi-cel vs SOC was associated with superior EFS (HR, 0.276, P<0.0001), and higher CR rates (75% vs 33%). Grade ≥3 TEAEs occurred in 94% and 82% of axi-cel and SOC pts, respectively
#lymphoma
#lymsm
0
13
30
CONGRESS
#EHA2024
|
@NitinJainMD
@MDAndersonNews
reports results of the phase 2 trial of pirtobrutinib, venetoclax & obinutuzumab in first-line treatment of pts with CLL. N=40, mFU=11.7 mo, 6 mo uMRD was 64% (PB=79%), 12-mo uMRD was 85% (PB=90%). Safety profile was similar to the
0
10
28
CONGRESS
#EHA2023
| Marco Ladetto
@UniAvogadro
talks about how to approach a patient with R/R follicular
#lymphoma
. Novel agents like T-cell engagers & rational combinations of existing treatments might further broaden therapeutic armamentarium.
#lym
#lymsm
@EHA_Hematology
0
15
28
CONGRESS |
#SOHO2024
Stephen M Ansell,
@MayoClinic
, discusses whether ABVD and BEACOPP are still relevant for the treatment of advanced stage Hodgkin
#lymphoma
. He believes that A(B)VD chemotherapy still has a role for low-risk patients, while younger patients or those with
0
14
29
CONGRESS
#EHA2024
| Tycel Phillips, MD (
@LymphClinician
) from
@cityofhope
presented an updated analysis of the phase I/II study of glofitamab for R/R
#mantlecelllymphoma
, demonstrating high response rates and durable responses in both BTKi-treated and -naïve pts. Majority of
1
10
29
CONGRESS|
#17ICML
Martin Hutchings(
@DocHutchings
),
@Rigshospitalet
presents the updated data on glofitamab plus polatuzumab vedotin in R/R DLBCL which led to high & durable responses & a manageable safety profile.
-Best responses: ORR of 78% & CR: 56%
-Mostly low-grade CRS
#lymsm
1
12
27
CONGRESS|
#17ICML
@Othman_Al_Sawaf
,
@UniCologne
presents the 6-yr results of the CLL14 study. Compared to Clb-Obi, fixed duration Ven-Obi showed a long-term PFS benefit across all subgroups of pts with previously untreated CLL, with no new safety signals reported
#lymsm
#lymphoma
1
10
27
CONGRESS |
@TheIACH
#IACH2024
| PRESENTATION
Andrew Davies
@AndyD1036
@UHSFT
shares insights on bispecific antibodies in patients with DLBCL.
They highlight key clinical trial data and discuss potential advantages over CAR T-cell therapies.
Follow our live feed for more updates:
0
9
28
#IACH23
| Laurence de Leval shares new insights into the molecular pathogenesis of PTCL. The presentation focuses on genetic susceptibility, signaling pathways, immune evasion, microenvironment, epigenetics, immune surveillance, and antigen stimulation in PTCL pathogenesis.
0
13
28
CONGRESS |
@TheIACH
#IACH2024
| PRESENTATION
Farrukh Awan
@awandoc
@UTSWMedCenter
discusses first-line therapy in patients with CLL.
They highlight the role of BTK inhibitors, anti-CD20 antibodies, BCL2 inhibitors, and potential combination therapies in patients with CLL, and
1
8
27
We would like to introduce our fantastic expert panel for the virtual
#LymHubSS
:
@gilles_salles
, Marie José Kersten,
@DunleavyKieron
, Francesc Bosch
@Sidnavigare
, and
@AstridPavlovsky
will be discussing ‘How I treat relapsed/refractory disease – DLBCL and CLL’
#ESHLYMPHOMA2020
0
11
25
📝 Results of the placebo-controlled, phase III ECHO study presented at
#EHA2024
showed that addition of acalabrutinib to bendamustine & rituximab significantly improved PFS in older pts with newly diagnosed
#MCL
More news:
#lymphoma
#lymsm
@MichaelWangMD
0
7
26
⏰ It’s almost time for the
@lymphomahub
Satellite Symposium
#LymHubSS
at 15-ICML 2019! Find out more here 👇 . See you there!
#Lymsm
0
5
21
CONGRESS |
#EHA2021
| Ulrich Jäger
@MedUni_Wien
describes pt selection & treatment of
#lymphoma
in the
#CARTcell
era. Pt, disease & treatment related factors are important in outcome. Use of CAR T-cell therapy in earlier lines of therapy should continue to improve outcomes
#lymsm
1
6
26
#ASH23
@gloria_iacoboni
discusses a comparison of response rates, survival outcomes and toxicity after CAR T (axi-cel, tisa-cel and liso-cel) accorrding to previous bispecific antibody exposure. N=47; PFS and OS was similar between control and CAR-T treated groups.
0
4
24
#SOHO2023
|
@DrJFriedberg
outlines treatment considerations and recommendations for older patients with Hodgkin
#lymphoma
and highlights the need for large trial data that can guide tx decisions in this population
#soho23
#lymsm
@WilmotCancer
0
12
25
#IACH23
|
#COLYM
Plenary Lecture |
@DrMiguelPerales
@MSKCancerCenter
presented an overview of the recent advances in allogeneic CAR T. Safety and efficacy of various novel CAR T and CAR NK cell therapies for
#MultipleMyeloma
, T- and B-cell malignancies, and solid tumors were
0
11
25
CONGRESS |
@TheIACH
#IACH2024
| PRESENTATION
Mariana Bastos-Oreiro
@DrBastosOreiroM
Gregorio Marañón Hospital, Madrid, provides an overview of CAR T-cell therapies for patients with DLBCL.
They discuss efficacy and safety results from clinical trials and real-world studies, and
0
7
25
CONGRESS |
#ASCO20
| GENUINE phase III trial |
@jeff_sharman
from
@WVCancer
, presented the final results of ublituximab (anti-CD20) + ibrutinib vs. ibrutinib alone in patients with high-risk R/R
#CLL
. The combination showed better results in terms of ORR, MRD-neg, and PFS
#lymsm
1
11
25
CONGRESS
#EHA2022
| Catherine Thieblemont
@HopSaintLouis
presented EPCORE-NHL-1 phase II study results of epcoritamab in pts with R/R LBCL. N=157, median follow-up=10.7 months, ORR=63%, CR=39%, low grade AEs including CRS
#lymsm
#lymphoma
0
6
25
CONGRESS
#CART22
@MediHumdani
,
@ASTCT
talked about second line treatment,
#CARTcells
or autologous transplant, in aggressive B-NHL
➡️auto HCT is a tested, relatively inexpensive option for
#DLBCL
with disease responding to salvage
➡️CART is SOC for refractory relapse
1
11
24
Congress |
#SOHO22
Alison Moskowitz from
@MSKCancerCenter
delivers an interesting talk on the novel agents brentuximab vedotin, nivolumab, and pembrolizumab, and how their introduction has changed the management of Hodgkin
#Lymphoma
#lymsm
#medicalcongress
0
8
24
CONGRESS
#ASCO24
| Jennifer Kimberly Lue
@MSKCancerCenter
reports subgroup analysis of genomic pattern from the POLARIX trial of Pola-R-CHP vs R-CHOP in pts with previously untreated DLBCL and extranodal (EN) disease. Distinct pattern of genetic mutations were present between
0
15
24
Are you up to date with the latest treatment options for second-line relapsed/refractory diffuse large B-cell
#lymphoma
?
Read our latest article to learn more!
1
8
24
CONGRESS |
#TCTM21
|
@JulioChavezMD
,
@MoffittNews
reported outcomes from the phase II ZUMA-5 study looking at the clinical efficacy of retreatment with axi-cel, an anti-CD19 CAR T cell therapy, for iNHL 👉 axi-cel retreatment demonstrated a 100% ORR in pts with iNHL.
#lymsm
1
11
24
#ASH18
Nitin Jain from
@MDAndersonNews
: combined venetoclax and ibrutinib is an effective, safe, and chemotherapy-free oral regimen for patients with high-risk treatment-naïve
#CLL
#lymsm
#lymphoma
0
11
24
CONGRESS |
#EHA25Virtual
| Andrea Kuhnl,
@KingsCollegeNHS
, presented the updated real-world experience of the outcomes of patients with high-grade lymphoma that receive CD19 CAR T therapy in the UK. She compared treatment responses from patients receiving axi-cel vs tisagen
#lymsm
0
7
24
CONGRESS |
#EHA2021
|
@MediHumdani
@MedicalCollege
argues for
#CARTcell
therapy for R/R DLBCL. He highlights that toxicity may be less with CAR T cells with TRM at 5% vs ~20% for allo-SCT. However he points out not either or. Pts who fail 1 may respond to other
#lymsm
#lymphoma
0
6
23
CONGRESS |
#ASCO20
| LYSA trial primary analysis, presented by
@Charles_Herbaux
(
@CHU_Lille
) demonstrate that the atezolizumab + obinutuzumab + venetoclax combination is well tolerated with efficacy comparable with currently available treatment options in R/R
#DLBCL
#lymsm
0
12
24
CONGRESS |
#CAR23
@MarcoRuella
,
@PennMedicine
presents a fascinating talk on resistance to CAR-T treatment in
#lymphoma
, with focus on tumor-intrinsic mechanisms, including antigen loss and apoptosis.
#lymsm
#medicalcongress
#hematology
0
11
24
CONGRESS
#EHA2023
|
@gilles_salles
@MSKCancerCenter
discusses a phase I/II trial of epocoritamab vs axi-cel in R/R DLBCL CAR-T naïve & eligible pts. There was no sig. difference in ORR or CR rates for CAR T-naive vs axi-cel. Results were similar for Ep vs Axi-cel
#lymsm
#lymphoma
3
13
23
CONGRESS |
#EHA24
| During the late-breaking abstracts session, Petra Langerbeins
@UniCologne
presented primary endpoint results of CLL12, phase III trial of ibrutinib vs placebo in asymptomatic CLL
#lymsm
#Lymphoma
@lymphomahub
#EHA2019
0
11
23
CONGRESS |
#16ICML
| Education session 📚
@gilles_salles
,
@sloan_kettering
, reviews strategies to improve
#CARTcell
treatment for patients with
#lymphoma
, firstly discussing characteristics impacting outcome
#lymsm
1
9
24
CONGRESS |
#EBMT20Virtual
|
@michaelwangmd
,
@MDAndersonnews
, presents the data from the latest follow-up of the ZUMA-2 study. KTE-X19 demonstrated a manageable safety profile and promising clinical efficacy in patients with R/R MCL.
#lymsm
1
7
22
CONGRESS |
@TheIACH
#IACH2024
| PRESENTATION
Graham Collins
@graham74GC
@OUHospitals
@OxfordCancer
examines first-line treatment in older/unfit patients with Hodgkin lymphoma.
They highlight some of the key challenges and considerations, and discuss a potential treatment
0
8
23
#ASH18
Philippe Armand from
@DanaFarber
establishes the robust anti-tumor activity of pembrolizumab in the treatment of
#PMBCL
, with durable responses and survival in responding patients, providing the basis for accelerated FDA approval
#lymsm
#lymphoma
0
15
21
CONGRESS |
#17ICML
Alex F Herrera
@cityofhope
presented results from the SWOG S1826 trial of nivolumab(N)-AVD vs brentuximab vedotin (BV)-AVD in pts with advanced-stage HL. 1-year PFS was 94% vs 86% in N‐AVD & BV-AVD, respectively with a manageable safety profile
#lymphoma
#leusm
1
10
23
132 talks, 37 interviews and 1
@lymphomahub
satellite symposium...
#15ICML
has been a great success! Thank you for all the fascinating talks and those who took part in an interview. Watch out over the coming week for articles and more expert interviews from the conference!
#lymsm
1
3
23
CONGRESS |
#PPLC21
| Christopher R. Flowers, University of Texas MD Anderson Cancer Center, provides a comprehensive comparison of BiTEs under development for the treatment of
#lymphoma
.
@MDAndersonNews
#lymsm
1
8
23
CONGRESS
#EHA2023
|
@DocHutchings
@Rigshospitalet
describes a phase II trial of glofitamab in pts with R/R LBCL. N=154. After a median FU =18.3 months, 39/59 pts who achieved CR were ongoing. Median duration of CR =24.1 months. 18-month OS rate =80%
#lymsm
#lymphoma
0
8
23
Great location, with even better presentations. The plenary abstracts award session
@EHA_Hematology
conference never fails to disappoint. A massive congratulations to all winners!
#EHA2023
#medicalcongress
0
4
23
CONGRESS
#ASCO24
| Peter Borchmann, MD
#cioabcd
presented the first report of the final analysis of phase III
#HD21
trial of PET2-individualized BrECADD regimen vs intensified BEACOPP in patients with advanced-stage
#HodgkinLymphoma
. BrECADD had superior efficacy (PFS 94.3% vs
0
16
23
#EHA2023
| Arnon Kater
@amsterdamumc
shares the final 7-year follow up data from the MURANO trial of VenR in R/RCLL. OS 69.6% and 51% in VenR and BR treated pts, respectively. PFS 23% VenR and 0% BR. Median PFS 23.3mo in VenR-retreated pts.
#CLL
#lymsm
1
12
21
CONGRESS |
#CART24
|
@DrMiguelPerales
@MSKCancerCenter
presented real-world experiences of CAR T-cell therapy including data on the grading systems, toxicity, efficacy, and prognostic models.
#lymphoma
#lymsm
#medicalcongress
0
6
20
The
@lymphomahub
team have now arrived in Orlando and we can’t wait for
#ASH19
to begin! Don’t miss our coverage of the meeting and the lymphoma and
#CLL
updates and advances!
#lymsm
0
6
22
Tomorrow is World
#Lymphoma
Awareness Day! Around the world, there are more than 735,000 people diagnosed with lymphoma, including CLL, every year. We will be joining
@knowyournodes
and the global community to thank those who help people with lymphomas!
#lymsm
#WLAD2020
0
10
21
CONGRESS
#EHA2022
|
@mike_dickinson1
presents the latest data of glofitamab, CD20xCD3 bispecific, in patients with r/r DLBCL and a median of 3 PL, including
#CARTcell
. The primary endpoint was met: fixed-duration treatment led to a 39.4% CR rate
#lymphoma
#lymsm
1
10
22
#ASCO23
OS analysis from the ZUMA-7 trial presented by
@Lymphoma_Doc
Axi-cel improves OS in 2L for refractory or early relapsed LBCL vs previous chemo-based regimen.
#lymsm
#CARTcells
1
12
21
CONGRESS |
#CART24
|
@Roberta04704608
@HopSaintLouis
discusses intensive care management strategies with CAR T-cell therapy. Infections, CRS, and ICANS were the main causes of ICU hospitalization in CAR T-cell recipients.
#lymphoma
#lymsm
#medicalcongress
1
13
22
#ASH23
@drsarahruth
summarizes results from pts with
#HL
≥60 years in the SWOG S1826. PFS in N-AVD vs Bv-AVD= 93% vs 64%; 1-yr OS in N-AVD vs Bv-AVD=95% vs 83%. Results support N-AVD as astandard of care treatment for older advanced HL patients fit for anthracycline-based
0
10
22